VitaNova Life Sciences (YJGJD) names CFO Steve Niu as director

Rhea-AI Filing Summary

VitaNova Life Sciences Corporation added its Chief Financial Officer, Steve Niu, to the Board of Directors effective February 19, 2026. He will serve as a director until the next annual stockholder meeting or earlier resignation or removal and will not receive additional compensation for this role.

The Board determined that Mr. Niu does not qualify as an independent director under Nasdaq corporate governance standards. He has served as VitaNova’s CFO since January 2024 and previously was President of Triangle Accounting, Inc. from 2001 to 2024, with extensive experience in U.S. and international taxation and regulatory compliance.

false 0001699709 0001699709 2026-02-19 2026-02-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 19, 2026

VitaNova Life Sciences Corporation

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-218733		35-2583762
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

39 E Broadway, Suite 603, New York, NY 10002

(Address of principal office)

+1-516-886-8888

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or former address if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		VNOV		OTC Pink Sheets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective February 19, 2026, the Board of Directors of VitaNova Life Sciences Corporation (the “Company”) appointed Steve Niu, the Company’s Chief Financial Officer, to serve as a director of the Company until the Company’s next annual meeting of stockholders or until his earlier resignation or removal . Mr. Niu will not receive any additional compensation for his service as a director.

Mr. Niu, age 64, has been our Chief Financial Officer since January 2024. Prior to joining the Company, Mr. Niu served as the President of Triangle Accounting, Inc. from 2001 to 2024. He specializes in U.S. federal and state taxation, international taxation, U.S. and Chinese regulatory compliance and foreign income consulting. He earned his Ph.D. and Master’s degree in Computer Information Systems  from Carleton University, Canada, in 2001 and 1998, respectively. In 1984, he graduated from Xi’an University of Science and Technology with a Bachelor’s degree in Mining Engineering. 

 Our Board of Directors of the Company has determined that Mr. Niu doesn’t qualify as an independent director, as defined under the applicable corporate governance standards of Nasdaq. There are no arrangements or understandings between Mr. Niu and any other persons pursuant to which he was appointed as director of the Company, and there are no family relationships involving Mr. Niu requiring disclosure under Item 404(a) of Regulation S-K.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 25, 2026

VitaNova Life Sciences Corporation
By:	/s/ Rose Kelly
	Rose Kelly
	Chief Executive Officer and Director (Principal Executive Officer)

3

FAQ

What board change did VitaNova Life Sciences (YJGJD) announce?

VitaNova Life Sciences appointed Chief Financial Officer Steve Niu to its Board of Directors effective February 19, 2026. He will serve as a director until the next annual stockholder meeting or his earlier resignation or removal, without receiving additional board compensation.

Is VitaNova Life Sciences (YJGJD) CFO Steve Niu considered an independent director?

No, the Board determined that Steve Niu does not qualify as an independent director under applicable Nasdaq corporate governance standards. This reflects his existing executive role as Chief Financial Officer rather than any disclosed conflict, and it affects how the Board’s independence profile is classified.

Will VitaNova Life Sciences (YJGJD) pay extra compensation to Steve Niu for board service?

VitaNova Life Sciences stated that Steve Niu will not receive any additional compensation for serving as a director. His remuneration remains tied to his existing role as Chief Financial Officer, meaning the board appointment does not add incremental direct cost for director fees.

What is the professional background of VitaNova Life Sciences (YJGJD) CFO Steve Niu?

Steve Niu has been VitaNova’s Chief Financial Officer since January 2024 and previously served as President of Triangle Accounting, Inc. from 2001 to 2024. He specializes in U.S. and international taxation, regulatory compliance, and foreign income consulting, with advanced degrees in Computer Information Systems.

Are there related-party or family relationships disclosed for VitaNova (YJGJD) director Steve Niu?

The company reported no arrangements, understandings, or family relationships involving Steve Niu that require disclosure. It specifically noted there are no family relationships requiring reporting under Item 404(a) of Regulation S-K, and no disclosed agreements with others for his appointment.

How long will Steve Niu serve on the VitaNova Life Sciences (YJGJD) board?

Steve Niu will serve as a director until VitaNova Life Sciences’ next annual meeting of stockholders or until his earlier resignation or removal. This is a standard board term structure tied to the timing of annual stockholder meetings rather than a fixed multi-year term.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB